{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T06:02:50Z","timestamp":1770789770286,"version":"3.50.0"},"reference-count":16,"publisher":"SLACK, Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmic Surg Lasers Imaging Retina"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.3928\/23258160-20260114-01","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T21:31:06Z","timestamp":1770759066000},"page":"73-76","source":"Crossref","is-referenced-by-count":0,"title":["RWC Update: GLP-1 Receptor Agonists and Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION): Concern or Coincidence?; The Glowport; Retinocytoma"],"prefix":"10.3928","volume":"57","author":[{"given":"Ashish","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihteh","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Stanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy X.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shishir","family":"Verghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prithvi","family":"Chandrakanth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dibya","family":"Prabha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kourous A.","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_2_2_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2964"},{"key":"e_1_2_2_2_14_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2296"},{"key":"e_1_2_2_2_14_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.6555"},{"key":"e_1_2_2_2_14_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.0350"},{"key":"e_1_2_2_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/19322968241268050"},{"key":"e_1_2_2_2_14_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.02.025"},{"key":"e_1_2_2_2_14_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2024.10.030"},{"key":"e_1_2_2_2_14_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2025.0349"},{"key":"e_1_2_2_2_14_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16316"},{"key":"e_1_2_2_2_14_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00620-x"},{"key":"e_1_2_2_2_14_12_2","doi-asserted-by":"publisher","unstructured":"Olchowska-Kotala A Uchmanowicz I Szczepanowski R. Verbal descriptors of the frequency of side effects: implementation of EMA recommendations in patient information leaflets in Poland. Int J Qual Health Care. 2022;34(1):mzac013. 10.1093\/intqhc\/mzac013 PMID:35277713","DOI":"10.1093\/intqhc\/mzac013"},{"key":"e_1_2_2_2_14_13_2","volume-title":"PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy","unstructured":"PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. European Medicines Agency (EMA). Published June 6, 2025. Accessed November 1, 2025. https:\/\/www.ema.europa.eu\/en\/news\/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy"},{"key":"e_1_2_2_2_14_14_2","volume-title":"Nation's ophthalmologists respond to European Agency's new recommendation","unstructured":"Should you stop taking GLP-1 drugs like Ozempic if you experience vision loss? Nation's ophthalmologists respond to European Agency's new recommendation. American Academy of Ophthalmology. Published July 7, 2025. Accessed November 1, 2025. https:\/\/www.aao.org\/newsroom\/news-releases\/detail\/should-you-stop-taking-glp-1-drugs-like-ozempic"},{"key":"e_1_2_2_2_14_15_2","volume-title":"GLP-1 receptor agonists and vision risk","unstructured":"GLP-1 receptor agonists and vision risk. American Optometric Association. Published July 10, 2025. Accessed November 1, 2025. https:\/\/www.aoa.org\/news\/clinical-eye-care\/public-health\/glp-1-receptor-agonists-and-vision-risk"},{"key":"e_1_2_2_2_14_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.26321"},{"key":"e_1_2_2_2_14_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14496"}],"container-title":["Ophthalmic Surgery, Lasers and Imaging Retina"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T21:31:07Z","timestamp":1770759067000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/23258160-20260114-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.3928\/23258160-20260114-01"],"URL":"https:\/\/doi.org\/10.3928\/23258160-20260114-01","relation":{},"ISSN":["2325-8160","2325-8179"],"issn-type":[{"value":"2325-8160","type":"print"},{"value":"2325-8179","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}